{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:19:12Z","timestamp":1781619552024,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.anai.2022.11.006","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T02:13:39Z","timestamp":1667787219000},"page":"215-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps"],"prefix":"10.1016","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4702-0343","authenticated-orcid":false,"given":"Patrick","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Menzies-Gow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju T.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Kuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus F.","family":"Rabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Altincatal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nami","family":"Pandit-Abid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juby A.","family":"Jacob-Nara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamo","family":"Deniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10258","key":"10.1016\/j.anai.2022.11.006_bib0001","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.anai.2022.11.006_bib0002","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/resp.13026","article-title":"Co-morbidities in severe asthma: clinical impact and management","volume":"22","author":"Porsbjerg","year":"2017","journal-title":"Respirology"},{"issue":"4","key":"10.1016\/j.anai.2022.11.006_bib0003","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1067\/mai.2002.122458","article-title":"Chronic sinusitis in severe asthma is related to sputum eosinophilia","volume":"109","author":"ten Brinke","year":"2002","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2022.11.006_bib0004","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1164\/rccm.201602-0419OC","article-title":"Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations","volume":"195","author":"Denlinger","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2022.11.006_bib0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12948-018-0103-x","article-title":"Comorbidities are associated with different features of severe asthma","volume":"16","author":"Novelli","year":"2018","journal-title":"Clin Mol Allergy"},{"issue":"5","key":"10.1016\/j.anai.2022.11.006_bib0006","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1183\/09031936.05.00037905","article-title":"Risk factors of frequent exacerbations in difficult-to-treat asthma","volume":"26","author":"ten Brinke","year":"2005","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2022.11.006_bib0007","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.anai.2022.11.006_bib0008","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jaci.2016.06.063","article-title":"Heterogeneous inflammatory patterns in chronic rhinosinusitis without nasal polyps in Chicago, Illinois","volume":"139","author":"Tan","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"14","key":"10.1016\/j.anai.2022.11.006_bib0009","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes","volume":"111","author":"Macdonald","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"10.1016\/j.anai.2022.11.006_bib0010","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.anai.2022.11.006_bib0011","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2022.11.006_bib0012","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc'h","year":"2020","journal-title":"Allergy"},{"issue":"26","key":"10.1016\/j.anai.2022.11.006_bib0013","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.anai.2022.11.006_bib0014","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2022.11.006_bib0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2022.11.006_bib0016","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.chest.2022.01.071","article-title":"Dupilumab reduces oral corticosteroid use in patients with corticosteroid-dependent severe asthma: an analysis of the phase 3, open-label extension TRAVERSE trial","volume":"162","author":"Sher","year":"2022","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.anai.2022.11.006_bib0017","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaip.2019.07.016","article-title":"Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis","volume":"8","author":"Maspero","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10209","key":"10.1016\/j.anai.2022.11.006_bib0018","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2022.11.006_bib0019","unstructured":"European Medicines Agency. DUPIXENT\u00ae (dupilumab). Summary of product characteristics. 2017. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dupixent-epar-product-information_en.pdf. Accessed July 14, 2022."},{"key":"10.1016\/j.anai.2022.11.006_bib0020","unstructured":"US Food and Drug Administration. DUPIXENT\u00ae (dupilumab). Highlights of prescribing information. 2022. Available at: https:\/\/www.regeneron.com\/sites\/default\/files\/Dupixent_FPI.pdf. Accessed July 14, 2022."},{"key":"10.1016\/j.anai.2022.11.006_bib0021","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13601-020-00330-1","article-title":"Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis","volume":"10","author":"Heffler","year":"2020","journal-title":"Clin Transl Allergy"},{"issue":"2","key":"10.1016\/j.anai.2022.11.006_bib0022","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaip.2018.08.021","article-title":"Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps","volume":"7","author":"Weinstein","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2022.11.006_bib0023","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/all.14902","article-title":"Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis","volume":"77","author":"Canonica","year":"2022","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2022.11.006_bib0024","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12890-019-0952-1","article-title":"Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis","volume":"19","author":"Numata","year":"2019","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.anai.2022.11.006_bib0025","doi-asserted-by":"crossref","DOI":"10.1177\/17534666211009398","article-title":"Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study","volume":"15","author":"Detoraki","year":"2021","journal-title":"Ther Adv Respir Dis"},{"issue":"1","key":"10.1016\/j.anai.2022.11.006_bib0026","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2017.04.009","article-title":"Oral corticosteroid exposure and adverse effects in asthmatic patients","volume":"141","author":"Sullivan","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2022.11.006_bib0027","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00019-2017","article-title":"Clinical and biological characteristics of the French COBRA cohort of adult subjects with asthma","volume":"50","author":"Pretolani","year":"2017","journal-title":"Eur Respir J"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120622019123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120622019123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:30:55Z","timestamp":1761053455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120622019123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1081120622019123"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2022.11.006","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2022.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}